Samchundang Pharmaceutical signs a term sheet with Dr. Reddy’s to collaborate on two liposome-based drug products. The agreement follows the companies’ prior partnership and aims to expand their joint development efforts in pharmaceutical innovation. Both firms specialize in advanced drug delivery systems, leveraging liposome technology for enhanced efficacy.
Sam Chun Dang Pharm has assumed the role of patent applicant for **S-PASS**, previously held by Summit Biotech. The transfer follows an industry dispute over ownership rights of the patent.
Samchundang Pharm files defamation charges against a blogger amid allegations linked to a failed contract. The company’s stock plummets to the daily trading floor, closing at its lowest limit. The lawsuit follows investor concerns over the contract’s impact on operations.
Sam Chun Dang Pharm’s stock price surges toward 100,000 won per share for the second consecutive day, driven by positive clinical trial developments. The company’s performance is propelling it to dominate the KOSDAQ market-cap rankings. Investors react to potential breakthroughs in its pipeline, though no specific trial results or product details are disclosed.
